|Mr. A. J. Kazimi||Founder, Chairman, Pres & CEO||787k||N/A||1958|
|Mr. Michael P. Bonner||CFO and Sr. Director of Fin. & Accounting||240.52k||N/A||1977|
|Mr. Leo B. Pavliv||Exec. VP of Operations & Chief Devel. Officer||490.24k||N/A||1961|
|Mr. James Lowrance Herman||Sr. VP of National Accounts & Chief Compliance Officer||310.65k||N/A||1955|
|Mr. Martin E. Cearnal||Exec. VP, Chief Commercial Officer & Director||381.74k||N/A||1945|
|Ms. Jean W. Marstiller||Sr. VP of Admin. Services & Corp. Sec.||N/A||N/A||1950|
|Ms. Cindy B. Patton||Sr. Director of Field Marketing||N/A||N/A||1953|
|Mr. John Michael Hamm||Director of Corp. Devel.||N/A||N/A||1934|
|Mr. Adam S. Mostafa||Managing Director||N/A||N/A||1980|
|Ms. Erin Smith Gull||Sr. Corp. Relations Associate||N/A||N/A||N/A|
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and rheumatology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ injection, for the treatment of certain serious bacterial infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. The company markets and sells its products through sales representatives and district managers. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Cumberland Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.